These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17701659)

  • 21. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of androgen on erythropoietin in patients with hypogonadism].
    Cui YG; Tong JS; Pan QQ; Di FS; Jia Y; Feng T; Liu Y; Wang XH; Zhang GY
    Zhonghua Nan Ke Xue; 2003; 9(4):248-51. PubMed ID: 12931361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone improves erectile function in hypogonadal patients with venous leakage.
    Kurbatov D; Kuznetsky J; Traish A
    J Androl; 2008; 29(6):630-7. PubMed ID: 18599885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Gooren L; Ernst M
    Aging Male; 2009 Dec; 12(4):113-8. PubMed ID: 19909203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study.
    Kalinchenko S; Vishnevskiy EL; Koval AN; Mskhalaya GJ; Saad F
    Aging Male; 2008 Jun; 11(2):57-61. PubMed ID: 18570056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with Andriol Testocaps--the first Austrian surveillance study on the treatment of late-onset hypogonadism.
    Jungwirth A; Plas E; Geurts P
    Aging Male; 2007 Dec; 10(4):183-7. PubMed ID: 18033627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men.
    Kornmann B; Nieschlag E; Zitzmann M; Gromoll J; Simoni M; von Eckardstein S
    J Androl; 2009; 30(5):602-13. PubMed ID: 19342702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
    Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
    J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss.
    Saad F; Haider A; Doros G; Traish A
    Obesity (Silver Spring); 2013 Oct; 21(10):1975-81. PubMed ID: 23512691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats.
    Misro MM; Chaki SP; Kaushik MC; Nandan D
    Contraception; 2009 Jun; 79(6):488-97. PubMed ID: 19442786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals.
    Brabrand S; Fosså SD; Cvancarova M; Lehne G
    BJU Int; 2011 Apr; 107(7):1080-7. PubMed ID: 20825398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration.
    Gava G; Mancini I; Cerpolini S; Baldassarre M; Seracchioli R; Meriggiola MC
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):878-886. PubMed ID: 30025172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.
    Brady BM; Amory JK; Perheentupa A; Zitzmann M; Hay CJ; Apter D; Anderson RA; Bremner WJ; Pollanen P; Nieschlag E; Wu FC; Kersemaekers WM
    Hum Reprod; 2006 Jan; 21(1):285-94. PubMed ID: 16172147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.
    Traish AM; Haider A; Doros G; Saad F
    Int J Clin Pract; 2014 Mar; 68(3):314-29. PubMed ID: 24127736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.